Loading
GV
Green Vision Biotechnology Corp. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by LAM CHING WAN, was filed 10 Feb 2022.
Green Vision Biotechnology Corp.: what insiders have been doing
Green Vision Biotechnology Corp. belongs to the Food & Agriculture sector. Filings by its managers are published through SEC (Form 4). Green Vision Biotechnology Corp. has had no insider filing for more than a year; the last one goes back to 10 February 2022.
Since 2021, the database holds 3 purchases and 3 sales by insiders of the company.
In the same sector, recent insider purchases at Village Farms International, Inc. also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
6
Thresholds
n/a
Buy Volume
€211,280
3 ops. · all time
Sell Volume
€261,345
3 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
Income statement
RevenueUS$124.9k
Gross profitUS$61.1k49% margin
Net income-US$430.3k-344.4% margin
Last declaration on 10 February 2022
Declarations6 total
75,674,200 shares@ US$0.003100.0% of flowCommon StockSEC:0001707195-22-000002:0
Canonical exit: 17 Apr 2022 (T+90)
75,674,200 shares@ US$0.00397.8% of flowCommon StockSEC:0001707066-22-000001:0
3,215,800 shares@ US$0.0032.9% of flowCommon StockSEC:0001707066-21-000001:1
21,894,200 shares@ US$0.00319.9% of flowCommon StockSEC:0001707066-21-000001:2
3,215,800 shares@ US$0.0032.9% of flowCommon StockSEC:0001707066-21-000001:3
Canonical exit: 26 May 2021 (T+90)
1,784,200 shares@ US$0.0032.2% of flowCommon StockSEC:0001707066-21-000001:0
Canonical exit: 26 May 2021 (T+90)
6 of 6 declarations
About Green Vision Biotechnology Corp.
GREEN VISION BIOTECHNOLOGY CORP. is a United States-incorporated company with a long and complex corporate history, best understood today as a small-cap, high-risk issuer with an agricultural and green-products orientation rather than a traditional large biotechnology platform. The company was incorporated in Nevada on July 5, 2012, originally under the name Any Translation Corp., and its early business focus was translation and interpretation services. It later changed its name to Vibe Wireless Corp. and then to Green Vision Biotechnology Corp. in 2016, reflecting a strategic repositioning toward environmentally oriented products and agricultural applications. According to SEC materials, GVBT describes itself as a pioneer in the research and development of green products, particularly bio-fertilizers for the agricultural sector in the People’s Republic of China, and it has also stated an intention to expand into trading agricultural products, cold storage, and related logistics activities. The company’s business address has been referenced in Hong Kong, underscoring that although it is legally organized in the United States, its operational footprint has been largely Asia-facing. From a competitive standpoint, GVBT appears to operate in a niche segment where scale, distribution access, and execution matter more than brand recognition. It does not appear to have the profile of a major NYSE or NASDAQ growth name; rather, it has the characteristics of a thinly followed micro-cap with a limited public information footprint. One of the most important recent developments is that the company announced in 2022 that it would voluntarily file Form 15 to suspend its SEC reporting obligations, citing a desire to reduce compliance costs and preserve resources for business operations and potential corporate transactions. That move materially reduces transparency versus fully reporting U.S.-listed peers. For investors, the key takeaways are the company’s incorporation in the United States, its evolving business model centered on agricultural bio-products and logistics, its Hong Kong-linked operating structure, and its recent emphasis on cost reduction and strategic flexibility. In short, GREEN VISION BIOTECHNOLOGY CORP. should be viewed as a small, restructuring-oriented agricultural biotech story with limited disclosure, not as a mainstream listed biotech company on NYSE or NASDAQ.
